China Journal of Leprosy and Skin Diseases ›› 2026, Vol. 42 ›› Issue (2): 111-113.doi: 10.12144/zgmfskin202602111

• Clinical Researches • Previous Articles     Next Articles

Spesolimab response in a child with acrodermatitis continua of Hallopeau harboring IL36RN gene mutation: a case report

WU Mingming1,2*, SUN Ruihan1,2*, WANG Yuan1,2, GUAN Xiao1,2, DU Guiying1,2, CHEN Zhan1,2, XIAO Jing1,2, WANG Jianqing3   

  1. 1 Shanxi Traditional Chinese Medical Hospital, Taiyuan 030012, China; 2 Shanxi Provincial Institute of Traditional Chinese Medicine, Taiyuan 030012, China; 3 Affiliated Hospital of Shanxi University of Chinese Medicine, Taiyuan 030024, China *Co-first authors
  • Online:2026-02-15 Published:2026-01-28

PDF (PC)

4

Like

Abstract: This paper reports a case of successful treatment of acrodermatitis continua of Hallopeau(ACH) in a pediatric patient using spesolimab. The patient,a 9-year-old boy with a disease history of over two years,had previously received oral traditional Chinese medicine, topical corticosteroids, antibiotics preparations with unsatisfactory results. Heterozygous intronic variant (c.115+6T＞C) and heterozygous missense variant (c.334G＞A) were identified in IL36RN gene. After intravenous administration of 450 mg spesolimab at weeks 0 and 4, the skin lesions significantly improved. During the one-year follow-up, the skin lesions resolved without recurrence, and no adverse reactions were observed.

Key words: acrodermatitis continua of Hallopeau, spesolimab, IL-36 inhibitor